The Inspire device treats obstructive sleep apnea by electrically stimulating the nerve that controls your tongue, timed to each breath you take during sleep. A small implanted pulse generator sends mild electrical signals through a cuff electrode wrapped around the hypoglossal nerve, causing the tongue to stiffen and push forward just enough to keep the airway open. It is sometimes described as a “pacemaker for sleep apnea,” and the comparison is apt: like a cardiac pacemaker, it sits under the skin near the collarbone and delivers precisely timed electrical pulses to solve a problem that used to require an external machine.
The Three Implanted Components
The Inspire system has three parts, each placed in a different location during a single surgery. The first is the stimulation electrode lead, a thin cuff that wraps around the medial branch of the hypoglossal nerve under the jaw. The second is the implantable pulse generator (IPG), which sits in the upper chest, typically on the right side just below the collarbone, much like a cardiac pacemaker. The third is a respiratory sensing lead, placed between the internal and external intercostal muscles on the ribcage, where it detects the rise and fall of breathing effort.1Operative Techniques in Otolaryngology-Head and Neck Surgery. Operative technique of upper airway stimulation: an implantable treatment of obstructive sleep apnea
The sensing lead is what makes the whole system responsive rather than just delivering stimulation on a fixed timer. It reads the expansion of your ribcage as you inhale, and the IPG uses that signal to fire the stimulation cuff at the right moment in the breathing cycle. The stimulation then relaxes as you exhale. This breath-synchronized approach means the tongue moves forward precisely when the airway is most likely to collapse during inhalation.2PubMed Central. Hypoglossal Nerve Stimulation Therapy for the Treatment of Obstructive Sleep Apnea
What Happens Inside the Airway
When the cuff electrode fires, it contracts the genioglossus and geniohyoid muscles, the primary muscles responsible for pushing the tongue forward. But the effect is not limited to the tongue itself. The contraction also pulls on the palatoglossus muscle, which connects the tongue to the soft palate, indirectly helping to stiffen and open the area behind the palate as well.3PubMed Central. Quality of Life Impact of Hypoglossal Nerve Stimulation with Inspire® Device in Patients with Obstructive Sleep Apnea Intolerant to Continuous Positive Airway Pressure Therapy
The tongue is an unusual piece of anatomy. It is a muscular hydrostat, a structure that maintains its volume while changing shape, somewhat like an octopus arm. Because of this, stimulating one set of muscles has cascading effects on the tongue’s shape and position. The posterior tongue in particular contains fatigue-resistant muscle fibers designed for sustained, low-level activity, which is why the stimulation can run all night without the tongue cramping or wearing out.4PubMed. Tongue anatomy and physiology, the scientific basis for a novel targeted neurostimulation system designed for the treatment of obstructive sleep apnea
Who Qualifies and How Screening Works
Not everyone with sleep apnea is a candidate for the Inspire implant. In the United States, patients must undergo a drug-induced sleep endoscopy (DISE) before implantation. During this procedure, you are sedated to simulate sleep while a doctor passes a small camera through the nose to watch exactly where and how the airway collapses.5PubMed. Supine Pharyngeal Width Is Associated With Complete Concentric Palatal Collapse During Drug-Induced Sleep Endoscopy and Hypoglossal Nerve Stimulator Outcomes
The critical finding doctors look for is something called complete concentric collapse at the palate, where the soft palate closes inward from all sides like a drawstring. When this pattern is present, the Inspire device does not work well, because the obstruction is happening above the tongue in a way that tongue protrusion cannot fix. In patients without this collapse pattern, the device dropped apnea events from roughly 38 per hour down to about 11 per hour. In patients with the concentric collapse, there was no meaningful improvement.6PubMed Central. Evaluation of Drug-Induced Sleep Endoscopy as a Patient Selection Tool for Implanted Upper Airway Stimulation for Obstructive Sleep Apnea
Beyond the DISE result, the general criteria include moderate to severe obstructive sleep apnea (typically 15 to 65 apnea events per hour), a body mass index under 35, age 18 or older, and documented difficulty tolerating or adhering to CPAP therapy. The BMI cutoff exists because excess tissue around the airway can limit how effectively the tongue movement opens things up.
The Surgery Itself
The implantation is performed under general anesthesia and typically takes two to three hours. Three incisions are made: one under the chin to access the hypoglossal nerve, one on the chest to create a pocket for the pulse generator, and one on the lower ribcage to place the sensing lead between the intercostal muscles.1Operative Techniques in Otolaryngology-Head and Neck Surgery. Operative technique of upper airway stimulation: an implantable treatment of obstructive sleep apnea Most patients go home the same day or the next morning. The device is not turned on immediately. Surgeons typically wait about a month after implantation to allow healing before activation.
Activation, Titration, and Nightly Use
Once activated, the device starts at low stimulation settings. You control it with a small handheld remote that lets you turn the device on at bedtime and off in the morning, with the option to adjust the stimulation intensity within a preset range. Most people set a brief delay timer so the stimulation does not begin until they have had time to fall asleep.
About three months after the device is turned on, you undergo a titration study, a sleep study specifically designed to fine-tune the stimulation settings. During this study, a technician adjusts the voltage, pulse width, and timing while monitoring your airway and breathing events, looking for the lowest effective stimulation level that keeps the airway open.7PubMed Central. Daytime polysomnography to perform titration for upper airway stimulation in patients with obstructive sleep apnea Some centers now use home sleep testing as an alternative to in-lab titration, reserving the full overnight lab study for patients who do not respond well to initial settings.8PubMed Central. Comparison of clinical pathways for hypoglossal nerve stimulation management: in-laboratory titration polysomnography vs home-based efficacy sleep testing
How Well It Works in Clinical Trials
The pivotal trial for the Inspire device, known as the STAR trial, enrolled patients with moderate to severe obstructive sleep apnea who could not tolerate CPAP. At 12 months, the median number of apnea events per hour dropped by about 68%, from 29.3 down to 9.0. Oxygen desaturation events fell by a similar margin.9PubMed. Upper-airway stimulation for obstructive sleep apnea At 18 months, the improvements held steady, with the median apnea events staying at roughly 9.7 per hour, confirming the results were not just an early honeymoon effect.10PubMed Central. Upper Airway Stimulation for Obstructive Sleep Apnea: Durability of the Treatment Effect at 18 Months
A secondary analysis of the STAR trial also found that the device reduced the body’s oxygen deprivation burden by about 77%, and it improved the lowest oxygen level reached during sleep by a few percentage points. Over 70% of participants saw their oxygen burden cut by more than half.11JAMA Otolaryngology–Head & Neck Surgery. Hypoglossal Nerve Stimulation and Hypoxic Burden in Patients With Obstructive Sleep Apnea: A Secondary Analysis of the STAR Trial
Real-World Results Outside the Trial
Clinical trials enroll carefully selected patients, so it is always worth asking whether results hold up in everyday practice. The ADHERE registry tracks Inspire outcomes across many medical centers in routine clinical use. In nearly 1,850 patients enrolled, the average apnea score dropped by about 21 events per hour, and daytime sleepiness scores improved substantially as well.12PubMed. Impact of Body Mass Index and Discomfort on Upper Airway Stimulation: ADHERE Registry 2020 Update
One of the more striking findings from the registry is how consistently patients actually use the device. Average nightly use came in around 5.6 to 6.4 hours per night, which compares favorably to typical CPAP use (which averages around 4 to 5 hours in most studies).13European Respiratory Journal. Post-approval upper airway stimulation predictors of treatment effectiveness in the ADHERE registry This makes intuitive sense: there is no mask to adjust, no hose to manage, no dry air blowing into your face, and no machine noise. You press a button on the remote and go to sleep.
How Sleep Quality Changes Beyond the Breathing Numbers
Reducing apnea events is the headline, but the downstream effects on sleep quality deserve attention. With untreated sleep apnea, you spend a disproportionate amount of time in the lightest stage of sleep because your brain keeps getting jolted by airway obstructions. After Inspire implantation, one study found that time spent in the lightest sleep stage dropped from about 23% to 16%, and REM sleep, the stage most disrupted by apnea, increased from about 9.5% to nearly 16%. Arousals from sleep also decreased.14PubMed. Effects of upper-airway stimulation on sleep architecture in patients with obstructive sleep apnea That REM recovery matters because REM sleep plays a major role in memory consolidation, mood regulation, and overall cognitive function. Many Inspire patients report that the improvement in how they feel during the day is even more noticeable than the reduction in snoring or apnea events.
Complications and What Can Go Wrong
Like any implanted device, things can go sideways. A review of adverse event reports submitted to the FDA found that the most common problems were infection at the surgical site, temporary nerve irritation or weakness (called neuropraxia), and fluid collection around the implant. Among the reported complications, roughly a third involved infection, about 15% involved nerve issues, and about 12% involved bleeding or fluid buildup. A significant portion of reported adverse events, around 42%, required a follow-up operation, most commonly to remove or reposition the device.15PubMed. Adverse events associated with the Inspire implantable hypoglossal nerve stimulator: A MAUDE database review
A separate analysis of the same FDA database identified some rare complications that had not been seen in the clinical trials, including pneumothorax (air leaking into the chest cavity from sensing lead placement) and lead migration into the chest cavity. Device migration, where the pulse generator shifts from its original position, was among the more common device-related reports.16PubMed. Adverse Events in Hypoglossal Nerve Stimulator Implantation: 5-Year Analysis of the FDA MAUDE Database
It is worth noting that FDA adverse event databases capture every reported problem, without adjusting for the total number of devices in use. They tend to overrepresent the complication rate because uneventful outcomes do not get reported. The STAR trial and ADHERE registry data suggest that serious complications are uncommon relative to the number of implants performed, but the surgical risks are real and should be discussed with your surgeon.
Inspire Versus CPAP
The Inspire device is not positioned as a first-line treatment for sleep apnea. It is designed for people who have already tried CPAP and could not tolerate it, whether because of claustrophobia, mask leak, skin irritation, aerophagia (swallowing air), or simply an inability to sleep with the apparatus. A systematic review and meta-analysis of long-term outcomes confirmed the device as a safe and effective option specifically for this population of adults with moderate to severe apnea who struggle with CPAP.17PubMed. Hypoglossal nerve stimulation long-term clinical outcomes: a systematic review and meta-analysis
That said, comparing the two directly is tricky. CPAP, when used correctly and consistently, essentially eliminates apnea events, reducing the count to near zero in most people. Inspire typically brings events down to somewhere between 5 and 10 per hour, which is a dramatic improvement from baseline but not the near-complete elimination that CPAP achieves. The trade-off is adherence: the best therapy in the world does nothing if it stays on the nightstand. And for many patients, nightly use of the implant runs an hour or two longer than their CPAP use ever did, simply because there is no discomfort barrier.
Use in Children and Adolescents With Down Syndrome
One of the more significant expansions of the Inspire device has been into younger patients with Down syndrome, a population that has high rates of obstructive sleep apnea and often does not respond well to standard treatments like adenotonsillectomy or CPAP. The FDA approved hypoglossal nerve stimulation for adolescents with Down syndrome aged 13 and older, and research is pushing the boundary even further.
A study of 42 adolescents with Down syndrome found that about 66% had their apnea events cut by half or more at 12 months, and roughly 73% reached fewer than 10 events per hour. Nightly device use averaged 9 hours, and the most common complaint was temporary tongue discomfort.18JAMA Otolaryngology–Head & Neck Surgery. Evaluation of Upper Airway Stimulation for Adolescents With Down Syndrome and Obstructive Sleep Apnea An earlier pilot study of six adolescents showed reductions in apnea events ranging from 56% to 85%.19JAMA Otolaryngology–Head & Neck Surgery. Hypoglossal Nerve Stimulation in Adolescents With Down Syndrome and Obstructive Sleep Apnea
More recently, a study examined the device in children with Down syndrome younger than 13. All 29 children were safely implanted, and among those with follow-up data, 95% saw their apnea events cut in half or more. The median apnea score dropped from about 18 to about 4 events per hour. There were no serious adverse events.20PubMed. Hypoglossal nerve stimulator for obstructive sleep apnea in children with down syndrome younger than 13 These are small studies, but the results are encouraging for a group of patients who previously had few good options.
Other Hypoglossal Nerve Stimulation Devices
Inspire is currently the only FDA-approved hypoglossal nerve stimulation system in the United States, but it is not the only approach that has been tried. At least two other devices have been developed. One, made by Apnex Medical, had a similar design to Inspire and showed promise in early trials but failed to meet effectiveness standards in its Phase III trial. The company eventually shut down. Another device, originally developed by ImThera Medical, uses a six-electrode cuff placed on the main trunk of the hypoglossal nerve rather than the medial branch, providing bilateral stimulation to both sides of the tongue.21PubMed Central. Insights since FDA Approval of Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea
Early data comparing bilateral stimulation (both sides of the tongue) to the unilateral approach used by Inspire found similar reductions in apnea events with no significant difference between the two approaches at three months.22PubMed Central. Bilateral vs Unilateral Hypoglossal Nerve Stimulation in Patients With Obstructive Sleep Apnea The bilateral approach has one interesting advantage: it does not require the respiratory sensing lead, because it delivers stimulation continuously at a low level rather than synchronizing it to breathing. That eliminates the sensing lead as a potential point of failure. Whether this translates into better long-term reliability or broader patient eligibility remains to be seen as more data accumulate.
Insurance, Cost, and Access
The Inspire device is expensive, with out-of-pocket costs for the surgery and hardware running into tens of thousands of dollars before insurance. Medicare has covered the procedure for eligible patients, and in practice, Medicare patients tend to have a smoother path to getting the device. One study found that Medicare patients waited an average of about 122 days from treatment recommendation to surgery, compared to roughly 201 days for those with private insurance. About 6% of Medicare patients were ultimately denied coverage, compared to 21% of privately insured patients.23PubMed. Does Insurance Status Impact Delivery of Care with Upper Airway Stimulation for OSA?
Private insurance coverage has been expanding, but the process often involves prior authorization, documented CPAP failure, and sometimes multiple appeals. The wait can be frustrating for patients who have already been through months or years of failed CPAP attempts and just want to move forward with a treatment that works. If you are considering the device, your surgical team’s insurance coordinator is often the most useful person to talk to early in the process, because they know which documentation the different payers require and how to avoid common denial triggers.
MRI Compatibility and Device Longevity
One practical question patients often raise is whether the implant is compatible with MRI scans. The current Inspire system is MRI conditional, meaning that scans can be performed under specific conditions (certain field strengths, body positioning, and scan parameters). This is similar to modern cardiac pacemakers. Your doctor and the MRI facility will need to coordinate to ensure the scan settings stay within the device’s safety parameters.
The pulse generator is battery-powered, and like a cardiac pacemaker, the battery has a finite life. Current estimates put battery longevity at roughly 11 years, though actual lifespan depends on the stimulation settings used. When the battery runs down, the IPG is replaced in a relatively minor outpatient procedure; the electrode leads typically do not need to be disturbed. This is a consideration worth factoring into the long-term cost picture, since a replacement surgery will be needed eventually.